TY - JOUR
T1 - Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort
T2 - The VaxiRIS study
AU - Cohen, Mikael
AU - Thomel-Rocchi, Océane
AU - Siva, Aksel
AU - Okuda, Darin T.
AU - Karabudak, Rana
AU - Efendi, Hüsnü
AU - Terzi, Murat
AU - Carra-Dalliere, Clarisse
AU - Durand-Dubief, Francoise
AU - Thouvenot, Eric
AU - Ciron, Jonathan
AU - Zephir, Helene
AU - Bourre, Bertrand
AU - Casez, Olivier
AU - De Seze, Jérôme
AU - Moreau, Thibault
AU - Neau, Jean Philippe
AU - Pelletier, Daniel
AU - Kantarci, Orhun
AU - Tutuncu, Melih
AU - Derache, Nathalie
AU - Bensa, Caroline
AU - Louapre, Celine
AU - Benoit, Jeanne
AU - Landes-Chateau, Cassandre
AU - Lebrun-Frenay, Christine
N1 - Publisher Copyright:
© The Author(s), 2023.
PY - 2023/8
Y1 - 2023/8
N2 - Background: Vaccination in patients with multiple sclerosis (MS) treated with immunosuppressive drugs is highly recommended. Regarding COVID-19 vaccination, no specific concern has been raised. Objectives: We aimed to evaluate if COVID-19 vaccination or infection increased the risk of disease activity, either radiological or clinical, with conversion to MS in a cohort of people with a radiologically isolated syndrome (RIS). Methods: This multicentric observational study analyzed patients in the RIS Consortium cohort during the pandemic between January 2020 and December 2022. We compared the occurrence of disease activity in patients according to their vaccination status. The same analysis was conducted by comparing patients’ history of COVID-19 infection. Results: No difference was found concerning clinical conversion to MS in the vaccinated versus unvaccinated group (6.7% vs 8.5%, p > 0.9). The rate of disease activity was not statistically different (13.6% and 7.4%, respectively, p = 0.54). The clinical conversion rate to MS was not significantly different in patients with a documented COVID-19 infection versus non-infected patients. Conclusion: Our study suggests that COVID-19 infection or immunization in RIS individuals does not increase the risk of disease activity. Our results support that COVID-19 vaccination can be safely proposed and repeated for these subjects.
AB - Background: Vaccination in patients with multiple sclerosis (MS) treated with immunosuppressive drugs is highly recommended. Regarding COVID-19 vaccination, no specific concern has been raised. Objectives: We aimed to evaluate if COVID-19 vaccination or infection increased the risk of disease activity, either radiological or clinical, with conversion to MS in a cohort of people with a radiologically isolated syndrome (RIS). Methods: This multicentric observational study analyzed patients in the RIS Consortium cohort during the pandemic between January 2020 and December 2022. We compared the occurrence of disease activity in patients according to their vaccination status. The same analysis was conducted by comparing patients’ history of COVID-19 infection. Results: No difference was found concerning clinical conversion to MS in the vaccinated versus unvaccinated group (6.7% vs 8.5%, p > 0.9). The rate of disease activity was not statistically different (13.6% and 7.4%, respectively, p = 0.54). The clinical conversion rate to MS was not significantly different in patients with a documented COVID-19 infection versus non-infected patients. Conclusion: Our study suggests that COVID-19 infection or immunization in RIS individuals does not increase the risk of disease activity. Our results support that COVID-19 vaccination can be safely proposed and repeated for these subjects.
KW - COVID-19
KW - Radiologically isolated syndrome
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85162719912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162719912&partnerID=8YFLogxK
U2 - 10.1177/13524585231179669
DO - 10.1177/13524585231179669
M3 - Article
C2 - 37322880
AN - SCOPUS:85162719912
SN - 1352-4585
VL - 29
SP - 1099
EP - 1106
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 9
ER -